Mammoth Biosciences raises $23 million for its CRISPR-based disease detection engine

Mammoth Biosciences, the biotech company that grew out of a close relationship with CRISPR legend Jennifer Doudna, has raised $23 million in a sturdy Series A. Mammoth previously raised $120,000 from NFX and the company continued quietly picking up funding as it built toward its exit from stealth mode in April 2018. Its current round was led by Mayfield with participation from NFX and 8VC.

Mammoth also has some high profile interest from individual investors. Apple’s Tim Cook and Jeff Huber, former CEO of early cancer screening company Grail, also quietly participated in the round for an unspecified amount.

The discovery of CRISPR, by all accounts a transformative scientific and technological breakthrough, is many things to many people, but for Mammoth Biosciences, it’s all about the search functionality.

CRISPR is biology’s search engine first,” Mammoth co-founder and CEO Trevor Martin told TechCrunch in an interview. That means using a guide RNA to direct a CRISPR protein to search for any specific DNA or RNA sequence. That process provides a world of utility across fields like genotyping, oncology, infectious disease and even agriculture.

Mammoth plans to use the funding to make key hires and flesh out its IP portfolio, but most of the company’s resources will be used toward developing the platform that allows the company’s partners to plug in and search for their own biomarkers. Martin adds that the funding will also allow Mammoth to educate people about how CRISPR can play a powerful role in diagnostics.